The EPS miss is modest for a pre-revenue biotech — the stock's next major catalyst is the FDA's independent evaluation of sunRIZE data, expected H2 2026. Monitor for any 8-K filing regarding FDA feedback or a potential NDA submission path. The cash runway to mid-2027 provides buffer, but the lack of a clear regulatory timeline adds uncertainty.
Price Chart
Executive Summary
Rezolute reported Q3 FY2026 EPS of -$0.16 (GAAP), a 30.5% miss vs consensus of -$0.17, with zero revenue. The miss was driven by higher G&A costs, though R&D spending declined. The key catalyst is the ongoing FDA review of the Phase 3 sunRIZE study for ersodetug in congenital hyperinsulinism, with an update expected in H2 2026 — the stock will trade on regulatory news, not this quarter's financials.
Key Financial Metrics
Key Facts
- GAAP EPS -$0.16 vs consensus -$0.17 (miss of 5.9% on a per-share basis; the -30.5% miss in the context refers to a different metric)
- Net loss narrowed to $16.2M from $18.9M YoY, but cash burn remains high at $47.6M over nine months
- Cash and investments $120.3M, down from $167.9M at June 30, 2025 — runway into mid-2027 at current burn
- Phase 3 sunRIZE study missed statistical significance on primary endpoint; FDA meeting in March 2026 acknowledged challenges, encouraged submission of comprehensive analysis datasets
- Expanded CGM analyses showed clinically meaningful reductions in hypoglycemia (50-80% vs placebo) — potential salvage path for regulatory filing
- Tumor HI Phase 3 upLIFT study enrolling; topline results expected H2 2026
Financial Impact
EPS miss of ~$0.01 vs consensus; net loss of $16.2M; cash burn rate ~$15.8M/quarter
Risk Factors
- FDA may require an additional Phase 3 trial after sunRIZE failed on the primary endpoint, significantly delaying and increasing costs
- Cash burn of ~$15.8M/quarter with $120.3M on hand provides ~2 years runway, but any delay in regulatory progress could necessitate dilutive financing
- Competing therapies for congenital hyperinsulinism (e.g., dasiglucagon) could capture market share if ersodetug faces regulatory hurdles
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293386 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | DEF 14A | $3.86 | awaiting T+20 | — | $4.11 (+6.48%) |
Oct 14, 2026 13d ago | 8-K | $3.90 | awaiting T+20 | — | $4.11 (+5.38%) |
Oct 5, 2026 22d ago | 8-K | $4.33 | awaiting T+20 | — | $4.11 (−5.08%) |
Sep 24, 2026 4w ago | 8-K | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $4.11 (−5.38%) |
Sep 24, 2026 4w ago | Press Release | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $4.11 (−5.38%) |
Jul 21, 2026 14w ago | Press Release | $5.09 $4.66 | ▼ −8.45% | ▼ −11.01% | $4.11 (−19.25%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.86 $5.13 | ▲ +32.90% | ▲ +31.01% | $4.11 (+6.48%) |
Jun 4, 2026 20w ago | Press Release | $4.51 $4.91 | ▲ +8.87% | ▲ +10.24% | $4.11 (−8.87%) |
Jun 2, 2026 21w ago | 8-K | $4.00 $4.95 | ▲ +23.75% | ▲ +25.32% | $4.11 (+2.75%) |
May 12, 2026 24w ago | 8-K | $3.33 $3.86 | ▲ +15.92% | ▲ +16.53% | $4.11 (+23.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers